Aligos Therapeutics, Inc. Revenue
Aligos Therapeutics, Inc. (ALGS) reported Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Aligos Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Aligos Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $2.83M, a 809.97% increase year-over-year.
- Aligos Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $169.00K, a 72.11% decline year-over-year.
- Aligos Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $741.00K, a 40.72% decline year-over-year.
- Aligos Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $2.19M, a 39.46% decline from fiscal 2024.
- Aligos Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $3.61M, a 41.67% decline from fiscal 2023.
- Aligos Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $6.19M.
- Aligos Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $2.83M 10-Q · filed 2026-08-06 | $3.00M derived: sum of 3 quarters · filed 2026-08-06 | $3.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.83M 10-Q · filed 2026-05-07 | $3.00M derived: sum of 2 quarters · filed 2026-05-07 | $3.74M derived: sum of 3 quarters · filed 2026-05-07 | $4.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $169.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $910.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.88M derived: sum of 3 quarters · filed 2026-08-06 | $2.19M 10-K · filed 2026-03-05 |
| 2025-09-30 | $741.00K 10-Q · filed 2025-11-06 | $1.71M derived: sum of 2 quarters · filed 2026-08-06 | $2.02M 10-Q · filed 2025-11-06 | $2.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $965.00K 10-Q · filed 2026-08-06 | $1.28M 10-Q · filed 2026-08-06 | $1.88M derived: sum of 3 quarters · filed 2026-08-06 | $3.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $311.00K 10-Q · filed 2026-05-07 | $917.00K derived: sum of 2 quarters · filed 2026-05-07 | $2.17M derived: sum of 3 quarters · filed 2026-05-07 | $3.23M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $606.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.86M derived: sum of 2 quarters · filed 2026-03-05 | $2.92M derived: sum of 3 quarters · filed 2026-03-05 | $3.61M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.25M 10-Q · filed 2025-11-06 | $2.31M derived: sum of 2 quarters · filed 2025-11-06 | $3.00M 10-Q · filed 2025-11-06 | $3.68M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.06M 10-Q · filed 2025-08-06 | $1.75M 10-Q · filed 2025-08-06 | $2.43M derived: sum of 3 quarters · filed 2025-08-06 | $3.51M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $694.00K 10-Q · filed 2025-05-06 | $1.37M derived: sum of 2 quarters · filed 2025-05-06 | $2.45M derived: sum of 3 quarters · filed 2025-05-06 | $6.75M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $672.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $1.76M derived: sum of 2 quarters · filed 2025-03-10 | $6.05M derived: sum of 3 quarters · filed 2025-03-10 | $6.19M 10-K · filed 2025-03-10 |
| 2023-09-30 | $1.08M 10-Q · filed 2024-11-06 | $5.38M derived: sum of 2 quarters · filed 2024-11-06 | $5.52M 10-Q · filed 2024-11-06 | $5.52M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $4.29M 10-Q · filed 2024-08-06 | $4.43M 10-Q · filed 2024-08-06 | $4.43M derived: sum of 3 quarters · filed 2024-08-06 | $4.43M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $140.00K 10-Q · filed 2024-05-07 | $140.00K derived: sum of 2 quarters · filed 2024-05-07 | $140.00K derived: sum of 3 quarters · filed 2024-05-07 | $140.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 derived: sum of 3 quarters · filed 2023-11-02 | $0.00 10-K · filed 2023-03-09 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2021-12-31 | $0.00 10-K · filed 2022-03-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |